Thermo Fisher Scientific CD27 Monoclonal Antibody (OTI3D6)

Applications

• Western Blot (WB): Tested dilution 1:250–1:500

Product Specifications

Product Specific Information

For reconstitution, add 100 µL distilled water to achieve a final antibody concentration of approximately 1 mg/mL.
For conjugation experiments using this carrier-free antibody, perform an additional desalting step (e.g., Zeba Spin Desalting Columns, 7K MWCO, 0.5 mL, Product #89882).

Target Information

CD27 is a 50 kDa member of the tumor necrosis factor (TNF) receptor superfamily, including CD40 and CD30. Members of this family regulate cell proliferation and death.
CD27 and its ligand CD70 are primarily expressed in lymphocytes, with CD27 expression dependent on antigen receptor ligation. CD70 expression requires additional co-stimulatory or pro-inflammatory signals.

CD27 is expressed as a disulfide-linked homodimer on mature thymocytes, peripheral blood T cells, and a subset of B cells. Activation of T cells via the TCR-CD3 complex increases CD27 expression and leads to the release of its soluble 28–32 kDa form (sCD27), detectable in plasma, urine, or spinal fluid. Soluble CD27 serves as a prognostic marker for acute and chronic B cell malignancies.

RgpA, a cysteine proteinase, can degrade CD27 and counteract T cell activation mediated by CD27-CD70 interaction. CD27-binding protein (SIVA), a proapoptotic protein, binds to CD27 and is involved in receptor-induced apoptosis.
Diseases associated with CD27 dysfunction include Lymphoproliferative Syndrome 2 and Autosomal Recessive Lymphoproliferative Syndrome.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.